The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of ifosfamide in combination with sorafenib in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Xavier Garcia del Muro
Consultant or Advisory Role - Bayer Schering Pharma
Research Funding - Bayer Schering Pharma
Joan Maurel
No relevant relationships to disclose
Javier Martinez Trufero
No relevant relationships to disclose
Javier Lavernia
No relevant relationships to disclose
Antonio Lopez-Pousa
No relevant relationships to disclose
Ramon De Las Penas
No relevant relationships to disclose
Ricardo Cubedo
No relevant relationships to disclose
Joaquin Fra
No relevant relationships to disclose
Antonio Casado
No relevant relationships to disclose
Ana De Juan
No relevant relationships to disclose
Laura Jimenez Colomo
No relevant relationships to disclose
Javier Martin Broto
No relevant relationships to disclose